The vast majority of biopharmaceutical proteins contain protein-linked sugars (glycans), which GlycoDelete technology remodels into small, homogenous 'handles' on the protein that impart new functionality either by themselves or upon coupling to other molecules. This GlycoDelete SBO consortium aims at exploiting this disruptive glyco-engineering technology for productiqn and testing of a range of improved biopharmaceuticals, as the basis for a spin-off company. The consortium consists of teams. with leading expertise in glyco­biotechnology, bio-organic chemistry, in vivo imaging and experimental medicine.
Effective start/end date1/05/1730/04/21

    Flemish discipline codes

  • Food sciences and (bio)technology not elsewhere classified

    Research areas

  • glyco-engineering

ID: 29143353